Boan Biotech Announces Publication of Phase 1 Clinical Study Results of BA5101 in the Journal of Expert Opinion on Biological Therapy

Recently, the results of the phase 1 clinical study of Dulaglutide Injection (BA5101, formerly coded LY05008) , a biosimilar of Trulicity® solely developed by Boan Biotech, were published in the journ...

Patient Enrollment Completed for BA9101 Phase 3 Clinical Study

Boan Biotech today announced that patient enrollment has been completed for the Phase 3 clinical study (comparative clinical study of efficacy and safety) of BA9101 (Aflibercept Intravitreous Injectio...

Voluntary Announcement Patient Enrollment Completed in the Phase 3 Clinical Study of BA9101 in China

Notice of Board Meeting

Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023

Boan’s BA2101 Administered for First Patient in Clinical Trial

Boan Biotech announced that BA2101, a self-developedinvestigational anti-IL-4Rα antibody , has been administered for the first patient in a Phase I clinical trial. Recognized as a Class 1 innova...

Boan’s BA1106 Administered for First Patient in Clinical Trial

Boan Biotech today announced that BA1106, aself developed investigational non-IL-2 blocking anti-CD25 antibody has been administered for the first patient in a Phase I clinical trial. This trial is de...

List of Directors and their Roles and Functions

Passing Away of a Non-Executive Director

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023